GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Cefiderocol (Fetroja)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

GlobalRPh RX List - FETROJA

Product / population
FETROJA intravenous cefiderocol in adults; renal function, intermittent HD and CRRT effluent are separate dosing contexts.
Renal method
Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-10
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

CRRT effluent guidance is not an intermittent-HD dose table

The selected official and mirror tables agree. Their CRRT guidance is explicitly initial and depends on effluent rather than a CrCl band.

What to reconcile: Confirm modality and L/hour effluent, then reassess residual function and clinical status; do not interpolate a new algorithm.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references

The recovered institutional page has different printed boundaries

The official label uses CrCl >=120; UCSF prints >120 beside 60-119. The upper effluent band is >=4.1 L/hour in the label versus >4 in UCSF.

What to reconcile: For exactly CrCl 120 the official label is explicit. Preserve the institutional discrepancy and seek clarification for effluent values between printed bands; do not interpolate. This is a wording/boundary comparison, not evidence of different clinical outcomes.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Rxlist

GlobalRPh RX List - FETROJA

Open original reference

GlobalRPh-hosted RX List · FETROJA intravenous cefiderocol in adults; renal function, intermittent HD and CRRT effluent are separate dosing contexts.

Renal method: Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Dialysis evidence: CRRT effluent-based initial regimen

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The retrieved mirror retains Cockcroft-Gault CrCl bands and separate CRRT effluent-flow recommendations. Its selected renal/CRRT tables agree with the separately retrieved official sections in this pass.

CRRT amounts are initial guidance, with residual kidney function and clinical status requiring reassessment. Retain effluent units in L/hour; do not substitute a weight-normalized effluent number or apply the intermittent-HD schedule to continuous therapy. The statement of selected-section agreement does not approve the full monograph.

RDM58-rxlist-cefiderocol-adc723a14a-C1 · Source locator: Dosage: renal adjustment Tables 1-2; Use in Specific Populations: Renal Impairment

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

A hosted label mirror is not independent corroboration of its underlying label. Official confirmation remains pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/fetroja-drug/
Retrieved
2026-09-10
Renal-function method
Cockcroft-Gault CrCl in mL/min; CRRT effluent in L/hour
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
9d4101a01526242c8da197ad7cf2928cad76591b1f06e5e8620d1d821d6eafff

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=cefiderocol&s1=RDM58-rxlist-cefiderocol-adc723a14a&h1=8f5bd5128c1c361ff5e11e7010e0a74ab781bbcdf19527edeea321677e54da89